Tasnim Rahman

Also affiliated with Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy”.

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010294

N/A

0.510DataRank · unranked

16 citations

Xiaoyan Deng, Dipankar Bandyopadhyay, Michael O. Idowu, Taylor M. Jenkins, Maciej Kmieciak +16 more

AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2 -associated metastatic HER2-negative breast cancer (BC).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.tps1143

N/A

0DataRank · unranked

0 citations

Adela Rodríguez Hernandez, Siddhartha Yadav, Ryan Buehler, Grace Augdahl, Tasnim Rahman +9 more